NCT06846034 Effect of Acute Hypoxia on Renal Hemodynamic in Healthy Volunteers, Patients With Diabetes and Patients With Diabetes and Kidney Disease
| NCT ID | NCT06846034 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Poitiers University Hospital |
| Condition | Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-02-13 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-02-13 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Diabetes mellitus is a non-transmissible disease whose incidence is growing worldwide . This pathology is defined by a chronic hyperglycaemia linked to a deficiency of either insulin secretion or its action or both. This increased prevalence is linked to the growing of the obese population on one hand, and to the ageing of the population, on the other hand, which is associated with an increased prevalence of metabolic diseases. The number of patients with diabetes, particularly type 2 diabetes (T2D) is regularly increasing. In France, the prevalence of diabetes is 4- 6% of the adult population. Diabetic kidney disease (DKD) is a growing public health problem and therefore constitutes a major factor in progressive kidney disease. DKD has become the leading cause of end stage kidney disease (ESKD), requiring dialysis or transplantation. Current routine screening for DKD is limited to detecting of impaired glomerular filtration rate (GFR) and/or elevated albuminuria, typically manifests in later stages of DKD. Therefore, the current methods to screen for DKD lack the resolution to capture the earliest functional changes associated with DKD. Chronic renal hypoxia plays a crucial role in the development and progression of DKD and may affect Renal hemodynamic. The aim to assess the feasibility of the measure of hypoxa-induced renal hemodynamics parameters.
Eligibility Criteria
Inclusion Criteria: For all participant : 1. No history of respiratory diseases 2. Affiliated person or beneficiary of the French social security scheme. 3. signed informed consent Group 1 ( For healthy volunteers): 1. \[18; 40\] years old 2. No history of diabetes 3. No acute/long term \> 3 months drug use except contraception 4. BMI: \[18,5 - 29,9\]kg/m2 5. eGFR \> 60ml/min/1.73m2 6. Normal to midly increased albuminuria: defined as ACR \< 3 mg/mmol For all the patients with T2D (group 2 and 3): 1. Diagnosed T2D according to ADA criteria 2. \[35; 75\] years old 3. Stable treatment of diabetes and/or antihypertension for at least 2 months prior to inclusion 4. No proliferative diabetic retinopathy Group 2 - For patients with T2D and no DKD: * eGFR \> 60ml/min/1.73m2 and * Normal to midly increased albuminuria: defined as ACR \< 3 mg/mmol Group 3 - For patients with DKD: * eGFR \[45-60 ml/min/1.73m2\] and/or * Moderately to severely increased ACR ≥ 3 mg/mmol Exclusion Criteria: For all participants: 1. Active smoking 2. Contraindication to any of the agent (PAH, or iohexol or gadolinium) used in the study. 3. Contraindication to cardiac MRI, renal MRI, respiratory tests, 4. History acute coronary syndrome or coronary revascularization 5. Recent (\<6 months) history of: Heart failure requiring hospitalisation or Stroke or transient ischemic neurologic disorder 6. Severe unstable hypertension (≥180 mmHg systolic or ≥110 mmHg diastolic blood pressure) 7. Resting oxygen saturation \<95% at baseline 8. Any concomitant disease or condition that may interfere with the safety or the possibility for the patient to comply with or complete the study protocol. 9. History of severe mountain sickness (dizziness, headache, nausea/vomiting and incapaciting fatigue) 10. Consumption of SGLT2 inhibitors 11. Concurrent participation in another clinical research study 12. Pregnant or breastfeeding women, women of childbearing age who do not have effective contraception 13. Persons benefiting from enhanced protection under french national law 14. Persons under psychiatric care who are unable to give their consent
Contact & Investigator
Pierre Jean SAULNIER, MD PhD
PRINCIPAL INVESTIGATOR
CHU Poitiers
Frequently Asked Questions
Who can join the NCT06846034 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06846034 currently recruiting?
Yes, NCT06846034 is actively recruiting participants. Contact the research team at emilie.rabois@chu-poitiers.fr for enrollment information.
Where is the NCT06846034 trial being conducted?
This trial is being conducted at Poitiers, France.
Who is sponsoring the NCT06846034 clinical trial?
NCT06846034 is sponsored by Poitiers University Hospital. The principal investigator is Pierre Jean SAULNIER, MD PhD at CHU Poitiers. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.